A record of what Emkay Global Financial Services Analysis said publicly, with the source. Not advice.
“Maintains a 'BUY' rating on Park Medi World, revising its June-27 price target up by 7% to ₹375 from ₹350, based on 21x June-28E EV/EBITDA. The brokerage highlights strong Q1FY27 performance with 19%/20% yoy revenue/EBITDA growth, agile acquisition playbook, focus on profitability, and ramp-up of new units. Expects 25% revenue CAGR over FY26-29E with ~1.8k bed additions over the next 18 months.”
Emkay Global Financial Services Analysis’s track record (trackable calls only): 179 graded calls · 95% CI 47–61%
How this call is judged
A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.
No entry price is stated, so the call starts at the first close after it was published.
Target ₹375, as stated.
Window: 328 days, the time frame the call states ("June-27").
Window still open: no verdict until a close reaches a level or the window ends.
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.